So, what is CDH17 and is it any good?
cb6e89a7-0df8-4318-9fda-ce72ad2df2e1.pdf (researchsquare.com)
5. Conclusions
In conclusion, this study provides further proofs to support the production and use of anti-CDH17 targeted immunotherapies such as CAR T cells against
CRCs.
No turning a cold cancer hot required such as IMU is doing with CF33 and then CD19 CAR-T, straight forward solid cancer fighting CAR-T.
Market ignoring this needs to be accepted at this stage but Hopper not fighting for CDH 17, AML and GBM is not acceptable.
CHM Science team - HERO, Hopper - Zero
GLTA
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $9.116K | 2.278M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 4987697 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 13474013 | 20 |
View Market Depth
| Last trade - 12.15pm 24/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |